Michael Mulqueen
Keine laufenden Positionen mehr
Karriereverlauf von Michael Mulqueen
Ehemalige bekannte Positionen von Michael Mulqueen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Biotie Therapies, Inc. | Corporate Officer/Principal | 01.01.2011 | 01.01.2015 |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Corporate Officer/Principal | 26.04.2010 | 01.01.2011 |
| ROCHE HOLDING AG | Corporate Officer/Principal | 01.01.1992 | 01.01.2005 |
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | 01.09.2017 | - |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Geschäftsführer | 26.04.2010 | - |
| Corporate Officer/Principal | 26.04.2010 | 26.04.2010 | |
The University of Liverpool
 The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | Geschäftsführer | - | 11.03.2010 |
| Undergraduate Degree | 11.03.2010 | - |
Statistik
International
| Vereinigte Staaten | 4 |
| Vereinigtes Königreich | 3 |
| Schweiz | 2 |
Operativ
| Corporate Officer/Principal | 5 |
| Chief Operating Officer | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private Unternehmen | 3 |
|---|---|
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Synosia Therapeutics, Inc.
Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Health Technology |
| Biotie Therapies, Inc. |
- Börse
- Insiders
- Michael Mulqueen
- Erfahrung